Insulet Co. (NASDAQ:PODD) Receives $267.44 Consensus PT from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $269.40.

PODD has been the subject of several recent research reports. Citigroup raised their price target on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Piper Sandler boosted their target price on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Raymond James upped their price target on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Barclays lifted their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Finally, BTIG Research raised their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th.

Insulet Stock Performance

NASDAQ PODD opened at $266.57 on Thursday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market cap of $18.70 billion, a P/E ratio of 45.65, a P/E/G ratio of 4.12 and a beta of 1.21. The stock has a 50-day moving average of $254.48 and a two-hundred day moving average of $222.96. Insulet has a 1-year low of $160.19 and a 1-year high of $279.77.

Insider Buying and Selling

In other news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.47% of the stock is owned by company insiders.

Institutional Trading of Insulet

A number of large investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new position in shares of Insulet in the second quarter valued at approximately $99,978,000. Baillie Gifford & Co. grew its position in Insulet by 30.8% in the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock valued at $380,607,000 after buying an additional 443,783 shares during the last quarter. Mizuho Securities USA LLC increased its stake in Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after buying an additional 320,416 shares during the period. Charles Schwab Investment Management Inc. raised its position in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after buying an additional 193,839 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its stake in shares of Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after acquiring an additional 163,388 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.